Kathleen Moore

Kathleen Moore, MD, MS is Associate Director of Clinical Research and Director of the Drug Development Program at Stephenson Cancer Center, University of Oklahoma, where she leads one of the most productive gynecologic oncology clinical trial programs in the United States. She is internationally recognized for her leadership of the ARIEL clinical trial program for rucaparib, particularly ARIEL4 — the definitive randomized phase III trial comparing rucaparib to investigator's choice chemotherapy in patients with BRCA1/2-mutant platinum-sensitive recurrent ovarian cancer. The ARIEL4 results helped define the clinical positioning of rucaparib and contributed to the regulatory landscape of PARP inhibitors in the second-line ovarian cancer setting. Dr. Moore has been a principal investigator on foundational ARIEL2 and ARIEL3 studies that established the LOH-high genomic scar biomarker for predicting PARP inhibitor benefit beyond BRCA mutation, broadening the biomarker framework for patient selection. She has also led phase I/II trials of novel agents including antibody-drug conjugates, folate receptor alpha inhibitors (mirvetuximab soravtansine), and immune combination regimens. Dr. Moore is highly active in GOG Foundation, NRG Oncology, and GCIG, contributing to design of multiple cooperative group phase III trials. She is a respected educator in gynecologic oncology drug development and a frequent invited speaker at ASCO, SGO, and ESMO.